Loading stock data…
FRE.DE
€40.32+0.07 (+0.17%)
Market OpenUpdated 9:58 AM EDT
Fresenius SE & Co.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fresenius SE & Co. KGaA in the Healthcare sector is trading at €40.11. The stock is currently near its 52-week low of €39.99, remaining 14.4% below its 200-day moving average. Technical signals show neutral RSI of 32 and bearish MACD signal, explaining why FRE.DE maintains its current current market pressure. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 32) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price€40.32
Potential Upside
31%
Whystock Fair Value€52.81
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Buy
Mean target€54.97+36.3%
Range€48.00 – €58.00
Fundamentals
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The F...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
€22.93B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
14.97
Beta
Defensive asset. Lower volatility than the S&P 500.
0.94
Div Yield
Strong income play. Yield provides a meaningful total return floor.
248.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.02%
Volume
Today's trading volume
224,829
Recent News
How The Fresenius SE KGaA (XTRA:FRE) Investment Story Is Evolving With Mixed Analyst Targets
The fair value estimate for Fresenius SE KGaA was trimmed slightly from €55.90 to €55.47 per share, a modest adjustment of about €0.43. This shift lines up with Street research that combines higher targets from bullish houses and €1 to €2 cuts from more cautious analysts, leaving the overall picture more balanced than before. As you read on, you will see how these different calls shape the evolving narrative around risk, reward, and what to watch next. Analyst Price Targets don't always...
Quest Diagnostics Q1 Earnings Call Highlights
Quest Diagnostics (NYSE:DGX) reported first-quarter 2026 results that management said reflected broad-based organic growth, improving productivity from automation and artificial intelligence, and contributions from major collaborations including Fresenius Medical Care and Corewell Health. The compan
Fresenius Medical Care AG (FMS) Looks to Improve Profitability After Smashing Q4 Expectations
Fresenius Medical Care AG (NYSE:FMS) is among the best German stocks to buy according to analysts. On February 24, Fresenius Medical Care AG (NYSE:FMS) released its Q4 2025 results. The company posted EPS of €1.14, compared to €0.23 in the same quarter in 2024. It delivered revenue of €5.1 billion, flat from the year-ago quarter. […]
Here's Why Fresenius (FMS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Assessing Fresenius SE KGaA (XTRA:FRE) Valuation After Recent Earnings And Shareholder Returns
Why Fresenius SE KGaA (XTRA:FRE) is Back on Investors’ Radars Fresenius SE KGaA (XTRA:FRE) has attracted fresh attention after posting annual revenue of €22.4b and net income of €1.1b, prompting investors to reassess how the healthcare group’s valuation compares with its recent performance. See our latest analysis for Fresenius SE KGaA. The 1 day share price return of a 0.8% decline and 7 day share price return of a 2.2% decline sit against a 30 day share price return of 9.1% and a 1 year...